Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 05 tags : Drug save search
Global $191 Billion Orphan Drugs Markets to 2026: Therapeutic Applications in Rare and Orphan Diseases, Regulatory Framework, Patents, and Innovations
Published: 2021-08-05 (Crawled : 20:00) - prnewswire.com
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -0.85%
H: 0.15%
C: -0.16%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.16%
H: 0.0%
C: 0.0%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.12%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -2.02%
H: 0.09%
C: -1.38%
disease drug patent application rare
Lung Cancer Drug Candidate Offers Patients Hope for Longer Life
Published: 2021-08-05 (Crawled : 17:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.14%
H: 0.3%
C: 0.22%
lung cancer cancer drug
Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome
Published: 2021-08-05 (Crawled : 16:00) - biospace.com/
SNPX | $4.33 -7.08% -7.62% 30K
|
Professional, Scientific, and T...
|
| O: 0.92%
H: 4.82%
C: -7.04%
drug trial syndros bryostatin
GoodRx Announces Agreement with Surescripts to Provide Real-Time Drug Discount Pricing in Electronic Health Records
Published: 2021-08-05 (Crawled : 13:15) - globenewswire.com
GDRX 4 | $6.69 -0.59% -0.6% 640K
|
Technology Services
|
| O: -0.76%
H: 1.6%
C: 0.63%
drug health
Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2021-08-05 (Crawled : 13:00) - biospace.com/
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.0%
H: 0.61%
C: 0.55%
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: 0.0%
H: 2.03%
C: 1.25%
new drug fda cancer drug fda acceptance
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
BTCM | $1.99 -6.13% 4.52% 75K
|
Arts, Entertainment, and Recrea...
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
UHS | $157.47 2.49% 4.13% 900K
|
Health Services
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
Your saved searches
Save your searches and get alerts when important news are released.